

Authera Enters into Research Agreement with argenx to Broaden Understanding of FcRn Biology

March 20- 2023, Oslo - Norway

Authera has entered into a research agreement with argenx to gain in-depth biologic insights into the complex biology of the neonatal Fc receptor (FcRn), which acts as a key homeostatic regulator of albumin and IgG antibody transport throughout our body.

Through the agreement, Authera will take advantage of a unique toolbox combined with knowledge from both parties. The purpose is to unravel how FcRn is orchestrating transport of its ligands in particular cells as well as how different protein modalities are handled in a cellular and in vivo context. Key research findings will be published in a joint effort in pre-reviewed journals.

"We are pleased to enter a research collaboration with such a forward-looking, global immunology-focused company with the common vision to unravel new molecular and cellular knowledge about FcRn, which we strongly believe will have far-reaching implications, and pave the way for development of tailored treatment options. It is a great validation of our technology platform, which is built on knowledge gained by academic-focused research over years", Simone Mester, co-founder and CEO.

About Authera

Authera AS is a pre-clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic biologics. The company's knowledge is based on the understanding of crucial biological processes involving FcRn combined with a high-end and sophisticated technology platform. This platform can educate and fine-tune molecular designs to secure their optimal FcRn mediated cellular transport behavior, which translates into favorable in vivo pharmacokinetic parameters in state-of-the-art mouse models. Authera is a spinout from the Laboratory of Adaptive Immunity and Homeostasis at University of Oslo and Oslo University Hospital, headed by Professor Jan Terje Andersen. Co-founders are Professor emerita Inger Sandlie, CEO Simone Mester and CSO Torleif Tollefsrud Gjøølberg. For more information, visit www.authera.no and follow us in LinkedIn and Twitter.

argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan.